Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.139 |
---|---|
High | 0.139 |
Low | 0.10 |
Bid | -- |
Offer | -- |
Previous close | 0.1375 |
Average volume | 56.46k |
---|---|
Shares outstanding | 10.88m |
Free float | 9.90m |
P/E (TTM) | -- |
Market cap | 1.50m USD |
EPS (TTM) | -7.54 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 20:04 BST.
More ▼
Announcements
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
- PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
- PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
- PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
- PaxMedica Announces 1-for-17 Reverse Stock Split
- PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
More ▼